Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02220114 : Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
PhaseN/A
AgesMin: 1 Month Max: 6 Years
Eligibility
Inclusion Criteria:

- Patients with diagnosed infantile spasms (IS) or pharmacoresistant partial onset
seizures (POS).

- Infants > 1 month and < 6 months; infants > 6 months and < 2 years; and children > 2
years and < 6 years.

- Patients stabilized under Sabril® for at least 2 weeks prior to V1: patients with no
spasms/POS or with a stable frequency of spasms/POS (i.e. with no more than 50%
variation in the number of spasms/POS) within 2 weeks prior to V1.

- Patients under a twice-a-day posology of Sabril®.

Non inclusion Criteria:

- Change in anti-epileptic treatment and/or Sabril® dose within 7 days before V1.

- Use of more than 2 other antiepileptic drugs as concomitant treatment (including
steroids). Ketogenic diet can be in addition to these 2 other antiepileptic drugs.

- Subjects receiving vigabatrin through a gastric tube.

- Weight < 4 Kgs.

- Any planned major surgery within the duration of the trial.

- Participation in any other clinical trial within 3 months prior to V1.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02220114      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740